Spain’s National Markets and Competition Commission has published a Study on the Retail Distribution of Medicine in Spain, where they analyze the various restrictions on competition that plague this market. The study concludes with a series of recommendations to improve efficiency in this sector.
The study finds that Spain’s current legislation imposes several restrictions on accessing, owning and maintaining a business in the drug retail market, causing a negative impact on competition and harming consumers.
The CNMC has, therefore, recommended the elimination of these restrictions on accessing the market: namely, the obligatory minimum distances between pharmacies and health providers; the elimination on restrictions on trading hours and advertising, and easing the requirements for opening a new pharmacy, among others.
Source: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI